Extracellular matrix hydrogel derived from decellularized tissues enables...

Paper

Abstract

Organoids have extensive therapeutic potential and are increasingly opening up new avenues within regenerative medicine. However, their clinical application is greatly limited by the lack of effective GMP-compliant systems for organoid expansion in culture. Here, we envisage that the use of extracellular matrix (ECM) hydrogels derived from decellularized tissues (DT) can provide an environment capable of directing cell growth. These gels possess the biochemical signature of tissue-specific ECM and have the potential for clinical translation. Gels from decellularized porcine small intestine (SI) mucosa/submucosa enable formation and growth of endoderm-derived human organoids, such as gastric, hepatic, pancreatic, and SI. ECM gels can be used as a tool for direct human organoid derivation, for cell growth with a stable transcriptomic signature, and for in vivo organoid delivery. The development of these ECM-derived hydrogels opens up the potential for human organoids to be used clinically.

Analysis

Paper intelligence

Summary

This paper presents decellularized tissue-derived extracellular matrix (ECM) hydrogels as a GMP-compliant system for expanding endodermal organoids, overcoming a major limitation for clinical applications.

Key findings

Decellularized tissue ECM hydrogels support the formation and growth of endodermal organoids.
These gels maintain a stable transcriptomic signature of the organoids.
ECM gels can be used for direct organoid derivation and in vivo delivery.
The developed hydrogels show potential for clinical translation of human organoids.

Methods

Decellularization of porcine small intestine mucosa/submucosa.
Formation of ECM hydrogels.
Culture of human endodermal organoids (gastric, hepatic, pancreatic, SI) in ECM gels.
Assessment of organoid growth and transcriptomic stability.
Evaluation of in vivo organoid delivery potential.

Limitations

The study focuses on endodermal organoids; applicability to other organoid types is not detailed.
While potential for clinical translation is highlighted, extensive validation for GMP compliance and in vivo efficacy may be required.

Applications

Regenerative medicine.
Drug discovery.
Toxicology studies.
Personalized medicine.

Confidence100%

Discovery